France's MedinCell FY revenue drops on lower milestone income
France's MedinCell FY revenue drops on lower milestone income
Overview
France biopharmaceutical firm's FY 2025-26 revenue fell 23% yr/yr as milestone income dropped
UZEDY royalties rose 42% yr/yr, driven by strong US sales and expanded indications
Company raised €48.2 mln in March 2026, boosting liquidity to €84.8 mln
Outlook
Company expects U.S. launch of Olanzapine LAI in Q4 2026, pending regulatory approval
MedinCell says AbbVie program expected to start clinical development in 2027
Company sees continued shift toward recurring royalty revenues as product portfolio expands
Result Drivers
UZEDY ROYALTY GROWTH - 42% yr/yr increase in UZEDY royalties driven by higher US sales and expanded indications
ABSENCE OF MILESTONE REVENUE - No milestone revenue booked this year versus €4.8 mln in prior year, largely explaining revenue decline
INCREASED OPERATING EXPENSES - Operating expenses rose 17% yr/yr due to higher R&D, platform investments, and scaling of commercial and support functions
Company press release: ID:nBw968yBka
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income |
| -EUR 31.29 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Medincell SA is €33.50, about 20.4% above its June 15 closing price of €27.82
The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 47 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)